Peptide Labs Inc. Review & Prices

A copper-binding tripeptide studied mainly in skin, hair-follicle, extracellular-matrix and cosmetic research.

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191 with an added tyrosine). It was developed to study growth hormone's effect on fat breakdown without its effects on growth or blood sugar, and reached human weight-loss trials before development stopped.

Sterile Water for Injection containing benzyl alcohol as a preservative, used as a diluent for compatible injectable medications.

BPC-157 is a 15-amino-acid peptide first described from gastric juice. Most of the published work is preclinical, with studies covering tendon, muscle, gastrointestinal, vascular, and other injury models. Researchers have looked at several signaling pathways, including VEGFR2, nitric oxide, Akt-eNOS, and ERK1/2 . Other work has focused on angiogenesis, fibroblast activity, endothelial responses, and inflammation. Human data are still sparse. Small studies have looked at knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics , but the number of human studies remains small and larger controlled trials are not available.

A BPC-157 and TB-500 blend, often called the "Wolverine Stack" is an informal combination of two synthetic peptides studied for tissue repair, cellular movement, and recovery

Cagrilintide is based on amylin , a hormone that helps regulate appetite and blood sugar after eating. Its structure was modified from natural amylin to make the peptide last longer. Unlike semaglutide, which mainly targets the GLP-1 receptor , cagrilintide acts through amylin and calcitonin-family receptors . Cagrilintide has also been studied on its own and together with semaglutide. Peptide Grading lists cagrilintide research materials from different suppliers. Listings can include supplier details, reported specifications, COA, quantities, shipping information, and price per mg .

An investigational combination of cagrilintide and semaglutide targeting amylin and GLP-1 pathways for obesity and metabolic research.

A nonapeptide studied for sleep architecture, stress response and neuroendocrine signaling, with mixed human evidence.

A synthetic tetrapeptide studied in aging, telomerase, circadian and cellular-biology research. Human evidence remains limited.

FOXO4-DRI is a modified peptide built from D-amino acids in reverse order (a 'D-retro-inverso' design). It blocks the binding of the FOXO4 protein to p53, which is studied as a way to make senescent ('zombie') cells self-destruct.